AU7465696A - Synthetic vaccine for protection against human immunodeficiency virus infection - Google Patents

Synthetic vaccine for protection against human immunodeficiency virus infection

Info

Publication number
AU7465696A
AU7465696A AU74656/96A AU7465696A AU7465696A AU 7465696 A AU7465696 A AU 7465696A AU 74656/96 A AU74656/96 A AU 74656/96A AU 7465696 A AU7465696 A AU 7465696A AU 7465696 A AU7465696 A AU 7465696A
Authority
AU
Australia
Prior art keywords
protection against
immunodeficiency virus
virus infection
human immunodeficiency
against human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74656/96A
Inventor
Barton F. Haynes
Thomas J Palker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/546,515 external-priority patent/US5993819A/en
Application filed by Duke University filed Critical Duke University
Publication of AU7465696A publication Critical patent/AU7465696A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AU74656/96A 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection Abandoned AU7465696A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/546,515 US5993819A (en) 1987-09-08 1995-10-20 Synthetic vaccine for protection against human immunodeficiency virus infection
US546515 1995-10-20
US59926696A 1996-02-09 1996-02-09
US599266 1996-02-09
PCT/US1996/016911 WO1997014436A1 (en) 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU72138/00A Division AU7213800A (en) 1995-10-20 2000-12-08 Synthetic vaccine for protection against human immunodeficiency virus infection

Publications (1)

Publication Number Publication Date
AU7465696A true AU7465696A (en) 1997-05-07

Family

ID=27068273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74656/96A Abandoned AU7465696A (en) 1995-10-20 1996-10-18 Synthetic vaccine for protection against human immunodeficiency virus infection

Country Status (5)

Country Link
EP (1) EP0868196A4 (en)
JP (1) JPH11515006A (en)
AU (1) AU7465696A (en)
CA (1) CA2235168A1 (en)
WO (1) WO1997014436A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814925C2 (en) * 1998-04-03 2000-10-05 Thomas Harrer Medicinal products for induction of cytotoxic T cells
MXPA02007478A (en) 2000-02-04 2004-08-23 Univ Duke Human immunodeficiency virus vaccine.
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
IL154991A0 (en) 2000-09-22 2003-10-31 Univ Duke Immunogen comprising ligand bound hiv envelope protein
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7153509B2 (en) 2001-11-07 2006-12-26 Duke University Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
AU2007352380A1 (en) * 2006-11-09 2008-11-06 Yasuhiro Nishiyama Binary epitope antibodies and B cell superantigen immune stimulants
US7892562B2 (en) 2008-10-08 2011-02-22 Karp Nelson M Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactiviated HIV-1 virions deficient in CD55 and CD59
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE373010T1 (en) * 1984-10-18 2007-09-15 Pasteur Institut GAG ANTIGEN AND ITS USE FOR DETECTING LAV INFECTION, AND IN IMMUNOGENIC COMPOSITIONS
ATE87103T1 (en) * 1985-12-17 1993-04-15 Akzo Nv IMMUNOCHEMICAL REAGENT.
WO1987007616A1 (en) * 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
DE69527708T2 (en) * 1994-04-29 2003-04-30 Univ Durham SYNTHETIC VACCINE TO PROTECT AGAINST INFECTION WITH THE HUMAN IMMUNE VIRUS

Also Published As

Publication number Publication date
JPH11515006A (en) 1999-12-21
EP0868196A1 (en) 1998-10-07
CA2235168A1 (en) 1997-04-24
WO1997014436A1 (en) 1997-04-24
EP0868196A4 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
AU5726694A (en) Human immunodeficiency virus decoy
AU4878096A (en) Hepatitis b vaccine
AU6304996A (en) Vaccines against hepatitis c
AU7557494A (en) Infection resistant medical devices
EP0744192A3 (en) Fall protection safety suit
AU6093296A (en) Infectious dengue 2 virus pdk-53 as quadravalent vaccine
HUP9601466A2 (en) Adjuvants for viral vaccines
LTIP335A (en) Vaccine for human immunodeficiency virus
HUP9601462A2 (en) Adjuvants for viral vaccines
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
AU7465696A (en) Synthetic vaccine for protection against human immunodeficiency virus infection
AU3154395A (en) Contraceptive vaccine
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU5848794A (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
EP0967993A4 (en) Anti-cocaine vaccine
AU2769595A (en) Contraceptive vaccine
AU5537996A (en) Hookworm vaccine
ZA96722B (en) Combination therapy for hiv infection
AU4602897A (en) Method for treatment of immunodeficiency virus infection
AU4450696A (en) Enhanced immunogenic vaccine
AU1194997A (en) Plasmid vaccine against pseudorabies virus
AU3552797A (en) Vaccine preparations
AU5520796A (en) Peptide-based vaccine against papillomavirus infection
AU5959494A (en) Vaccines against sterols

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted